Nick Vidnovic

Nick Vidnovic(2002)


Harvard U, 2007 — AB cum laude in Chemistry

Employer/Job Title

Curently an Associate with The Boston Consulting Group in
Boston; joining Bain Capital Private Equity in the fall.


During college I did a signigicant amount of work in molecular biology studying transcriptional regulation in non-Hodgkins lymphoma
and breast cancer. I have been an author on 4 papers based on my work. Links to the PubMed summaries are below. The second one
listed (on p63/p73) was my main research interest. I also was acknowledged on a Genes/Dev paper from that lab.
-Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin’s lymphoma. Jacobs SA, Harrison
AM, Swerdlow SH, Foon KA, Avril N, Vidnovic N, Joyce J, DeMonaco N, McCarty KS Jr. Mol Imaging Biol. 2009 Jan-Feb;11(1):39-45.
Epub 2008 Sep 5.
-The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. Leong CO,
Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. J Clin Invest. 2007 May;117(5):1370-80. Epub 2007 Apr 19.
-Durable remission of HIV-negative, Kaposi’s sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid
arthritis treated with methotrexate. Jacobs SA, Vidnovic N, Patel H, Soma LA, Chang Y, Bass N, Swerdlow SH. Clin Rheumatol. 2007
Jul;26(7):1148-50. Epub 2006 Jul 6.
-Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Jacobs SA, Vidnovic N, Joyce J,
McCook B, Torok F, Avril N. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7146s-7150s.